Our Pipeline

Menu

A robust pipeline of ADCs intended for the treatment of hematological cancers and solid tumors

ADC Therapeutics is advancing a portfolio of investigational ADCs including those which utilize our highly potent pyrrolobenzodiazepine (“PBD”) technology, a differentiated exatecan-based payload with a novel hydrophilic linker and a next generation ADC toolbox.

Pre-clinical candidates targeting Claudin-6, NaPi2b, PSMA and ASCT2 are based on an innovative proprietary approach which utilizes exatecan with a novel hydrophilic linker as a highly potent and differentiated payload.

By leveraging decade-long expertise in the ADC field with multiple INDs and a proven track record of success, ADC Therapeutics continues building this toolbox with new antibody formats, linkers and toxins while advancing a range of payloads, linkers and conjugation technologies against multiple targets to develop differentiated next-generation assets.

The agents represented in this pipeline chart are investigational. Efficacy and safety have not yet been established.

Preclinical

Phase 1a

Phase 1b

Phase 2

Phase 3/
Confirmatory

ZYNLONTA

ZYNLONTA® (Loncastuximab Tesirine-lpyl) Targeting CD19

LOTIS-2 in 3L+ r/r DLBCL

ClinicalTrials.gov identifier: NCT03589469

Preclinical

Phase 1a

Phase 1b

Phase 2

Phase 3/
Confirmatory

FDA Approved

LOTIS-5 with rituximab in r/r NTE DLBCL

ClinicalTrials.gov identifier: NCT04384484

Preclinical

Phase 1a

Phase 1b

Phase 2

Phase 3/
Confirmatory

Confirmatory

LOTIS-7 in non-Hodgkin Lymphoma

ClinicalTrials.gov identifier: NCT04970901

Preclinical

Phase 1a

Phase 1b

Phase 2

Phase 3/
Confirmatory

PBD-Based

ADCT-602*
Targeting CD22

Acute Lymphoblastic Leukemia

ClinicalTrials.gov identifier: NCT03698552

Preclinical

Phase 1a

Phase 1b

Phase 2

Phase 3/
Confirmatory

Exatecan Platform

Claudin-6

Adhesion protein

Preclinical

Phase 1a

Phase 1b

Phase 2

Phase 3/
Confirmatory

IND-enabling

PSMA

Enzymatic glycoprotein

Preclinical

Phase 1a

Phase 1b

Phase 2

Phase 3/
Confirmatory

IND-enabling

NaPi2b

Phosphate transporter

Preclinical

Phase 1a

Phase 1b

Phase 2

Phase 3/
Confirmatory

IND-enabling

ASCT2

Amino Acid Transporter

Preclinical

Phase 1a

Phase 1b

Phase 2

Phase 3/
Confirmatory

Drug-candidate selection

* The ADCT-602 trial is being led by the University of Texas MD Anderson Cancer Center.

  Anticipated milestones set forth in this chart are subject to further future adjustment based on, among other factors, the impact of the COVID-19 pandemic.
NTE: Non-Transplant Eligible.

For more information on our clinical trials visit adctmedical.com

Loncastuximab tesirine-lpyl

Loncastuximab tesirine-lpyl is an ADC composed of a humanized monoclonal antibody that binds to human CD19 and is conjugated through a linker to a PBD–dimer toxin. Once bound to a CD19-expressing cell, loncastuximab tesirine-lpyl is internalized into the cell, where enzymes release the PBD-based warhead. The warhead is designed to bind irreversibly to DNA to create highly potent interstrand cross-links that block DNA strand separation, thus disrupting essential DNA metabolic processes such as replication. This ultimately results in cell death.

The LOTIS clinical trial program

Lotis 1, Image

[402-101] – A Phase 1 Dose-escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non-Hodgkin Lymphoma (B-NHL)

NCT02669017
COMPLETED

Lotis 2, Image

[402-201] – A Phase 2 Open-label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine-lpyl in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

NCT03589469
ACTIVE, NOT RECRUITING

Lotis 5, Image

[402-311] – A Phase 3 Randomized Study of Loncastuximab Tesirine-lpyl Combined With Rituximab Versus Immunochemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

NCT04384484
RECRUITING

A Phase 1b, Open-label Study to Evaluate the Safety and Efficacy of Loncastuximab Tesirine-lpyl in Combination With Other Anticancer Agents in Patients with Relapsed or Refractory B-cell Lineage Non-Hodgkin Lymphoma (B-NHL)

NCT04970901
RECRUITING

ADCT-602 targeting CD22

ADCT-602 is an ADC composed of a monoclonal antibody that binds to CD22 conjugated to a PBD–dimer toxin. Once bound to a CD22-expressing cell, ADCT-602 is internalized into the cell where enzymes release the PBD-based warhead. CD22 is an attractive and clinically validated ADC target. CD22 is highly expressed on most malignant B-cells, including expression in more than 90% of patients with B-cell acute lymphoblastic leukemia (ALL).

ADCT-602 is being evaluated in a phase I/II clinical trial in patients with relapsed or refractory B-cell ALL (NCT03698552). The trial is being led by The University of Texas MD Anderson Cancer Center.

ADCT-602 targets CD22, Diagram